BioWorld

July 17, 2009

The 'Rights' Stuff: Offering Gains Pharmacyclics $24M

Rebounding from its 2007 troubles with lung cancer drug Xcytrin, Pharmacyclics Inc. has emerged with a retooled management team, a multiproduct pipeline and a rather unusual - at least for biotech - money-raising strategy. (BioWorld Today) Read More

Amgen to Face Bundling Hits; CMS Rule Tolerable for Others

Tysabri Sales Stay Strong in a Good Biogen Quarter

NewCo News: AngioChem Crossing Barriers in Efforts to Heal the Brain

BDSI's Cancer Pain Film Onsolis Wins FDA OK

Clinic Roundup

Appointments And Advancements

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 8, 2026.

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...